LifeStance Health Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LifeStance Health Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.42B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.25B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.06B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $859.54M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $667.51M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $265.56M | Mar 9, 2023 |
| FY2022 | May 14, 2020 | $111.66M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $212.52M | Mar 17, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.45M | Mar 17, 2022 |
| FY2021 | Dec 31, 2020 | $142.0K | Mar 17, 2022 |
| FY2021 | May 14, 2020 | $14.0K | Mar 17, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.66M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($57.44M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($186.26M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($215.56M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($307.20M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($13.13M) | Mar 9, 2023 |
| FY2022 | May 14, 2020 | ($24.95M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $5.67M | Mar 17, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.15M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($31.61M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($189.13M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($210.17M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($286.35M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $6.74M | Mar 9, 2023 |
| FY2022 | May 14, 2020 | $8.70M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $15.24M | Mar 17, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $382.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $363.06M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $410.79M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $377.99M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $433.73M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $51.84M | Mar 9, 2023 |
| FY2022 | May 14, 2020 | $20.85M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $41.06M | Mar 17, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.15M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $107.26M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($16.88M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $52.79M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $9.42M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($21.97M) | Mar 9, 2023 |
| FY2022 | May 14, 2020 | $13.44M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $17.05M | Mar 17, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.13M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $21.57M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $40.52M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $79.26M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $94.49M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $25.26M | Mar 9, 2023 |
| FY2022 | May 14, 2020 | $12.80M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $14.31M | Mar 17, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.20B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $2.12B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $2.11B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.17B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.93B | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $1.57B | Mar 17, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $682.92M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $672.01M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $681.04M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $655.15M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $382.08M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $536.90M | Mar 17, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.52B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.45B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.43B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.52B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.55B | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $997.84M | Mar 17, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.29B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.29B | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $1.27B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.20B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.10B | Mar 9, 2023 |
| FY2022 | May 14, 2020 | $926.66M | Mar 9, 2023 |
| FY2021 | Apr 13, 2020 | $0 | Mar 17, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($808.63M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($818.29M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($760.85M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($572.64M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($357.07M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($13.13M) | Mar 17, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $248.64M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $154.57M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $78.82M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $108.62M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $148.03M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $18.83M | Mar 17, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $282.75M | Feb 25, 2026 |
| FY2024 | Dec 31, 2024 | $290.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $289.49M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $233.96M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $161.23M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $373.82M | Mar 17, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 388.32M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 382.74M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 378.73M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 375.96M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 374.26M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 17, 2022 |